U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H29FO5
Molecular Weight 392.4619
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXAMETHASONE

SMILES

C[C@]1([H])C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@]3([C@]([H])(C[C@]2(C)[C@]1(C(=O)CO)O)O)F

InChI

InChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H29FO5
Molecular Weight 392.4619
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune response. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
MAXIDEX

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

-237859200000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237859200000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
Neofordex

Approved Use

Neofordex is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.

Launch Date

1458000000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.87 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51.2 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.93 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
DEXAMETHASONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
96 mg multiple, oral
Dose: 96 mg
Route: oral
Route: multiple
Dose: 96 mg
Sources:
unhealthy, 63 years (range: 30–78 years)
Health Status: unhealthy
Age Group: 63 years (range: 30–78 years)
Sex: M+F
Sources:
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Sources:
Other AEs: Corneal erosion...
Other AEs:
Corneal erosion (10%)
Sources:
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
Other AEs: Constipation...
Other AEs:
Constipation (below serious, 1 patient)
Sources:
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Drowsiness, Dizziness...
Other AEs:
Drowsiness (below serious, 19 patients)
Dizziness (below serious, 3 patients)
Adverse drug reaction NOS (below serious, 10 patients)
Sources:
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Wound dehiscence...
Other AEs:
Wound dehiscence (below serious, 1 patient)
Sources:
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Dizziness...
Other AEs:
Dizziness (below serious, 1 patient)
Sources:
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Constipation, Dyspepsia...
Other AEs:
Constipation (below serious, 47 patients)
Dyspepsia (below serious, 12 patients)
Vomiting (below serious, 9 patients)
Fatigue (below serious, 58 patients)
Cholesterol high (below serious, 8 patients)
Anorexia (below serious, 15 patients)
Anxiety (below serious, 11 patient)
Insomnia (below serious, 26 patients)
Cough (below serious, 9 patients)
Dyspnea (below serious, 20 patients)
Sources:
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Other AEs: Incision site bleeding, Body temperature decrease...
Other AEs:
Incision site bleeding (below serious, 1 patient)
Body temperature decrease (below serious, 2 patients)
Shivering (below serious, 1 patient)
Tachycardia (below serious, 1 patient)
Transfusion (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Corneal erosion 10%
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Sources:
Constipation below serious, 1 patient
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
Adverse drug reaction NOS below serious, 10 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
Drowsiness below serious, 19 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness below serious, 3 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
Wound dehiscence below serious, 1 patient
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness below serious, 1 patient
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anxiety below serious, 11 patient
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspepsia below serious, 12 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anorexia below serious, 15 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspnea below serious, 20 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Insomnia below serious, 26 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Constipation below serious, 47 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue below serious, 58 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cholesterol high below serious, 8 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cough below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vomiting below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Incision site bleeding below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Shivering below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Tachycardia below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Transfusion below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Body temperature decrease below serious, 2 patients
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: These data demonstrate that dexamethasone at doses used clinically increased CYP3A4 activity with extensive intersubject variability and that the extent of CYP3A4 induction was, in part, predicted by the baseline activity of CYP3A4 in both healthy volunteers and human hepatocyte cultures.
Page: -
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Blockade of cocaine-induced increases in adrenocorticotrophic hormone and cortisol does not attenuate the subjective effects of smoked cocaine in humans.
1999 Sep
Antenatal dexamethasone improves atrial natriuretic peptide receptors in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
2000
Immune abnormalities in aneurysmal subarachnoid haemorrhage patients: relation to delayed cerebral vasospasm.
2000 Apr
Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender.
2000 Aug
Dexamethasone enhances ras-recision gene expression in cultured murine fetal lungs: role in development.
2000 Aug
Dexamethasone suppresses tumor necrosis factor-alpha-induced apoptosis in osteoblasts: possible role for ceramide.
2000 Aug
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
2000 Aug
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Effects of dexamethasone on mitogen-activated protein kinases in mouse macrophages: implications for the regulation of 85 kDa cytosolic phospholipase A(2).
2000 Aug 15
Dexamethasone-suppressible hypertension.
2000 Aug 26
Suppressive effect of active hexose correlated compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat.
2000 Dec
Effect of endogenous and exogenous prostaglandin E(2) on interleukin-1 beta-induced cyclooxygenase-2 expression in human airway smooth-muscle cells.
2000 Dec
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma.
2000 Dec 15
Prenatal exposure to high levels of glucocorticoids increases the susceptibility of cerebellar granule cells to oxidative stress-induced cell death.
2000 Dec 19
Effect of polyunsaturated fatty acids on dexamethasone-induced gastric mucosal damage.
2000 Feb
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review.
2000 Jul 29
Dexamethasone induced cardiac hypertrophy in newborn rats is accompanied by changes in myosin heavy chain phenotype and gene transcription.
2000 Jun
Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up.
2000 Jun
Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing.
2000 Jun
Down-regulation of thyroid transcription factor-1 gene expression in fetal lung hypoplasia is restored by glucocorticoids.
2000 Jun
Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding.
2000 Jun 23
beta(3)-adrenoceptor regulation and relaxation responses in mouse ileum.
2000 Mar
Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line.
2000 Mar
Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney.
2000 Mar
Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism.
2000 May
Effects of selected herbicides on cytokine production in vitro.
2000 May 19
Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands.
2000 May 19
Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.
2000 May-Jun
Corticosteroids and cognitive function in humans: methodological considerations.
2000 May-Jun
Regulation of leptin release by troglitazone in human adipose tissue.
2000 Nov
Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon.
2000 Nov
Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats.
2000 Nov
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.
2000 Nov 10
Dexamethasone-induced cardiogenic shock rescued by percutaneous cardiopulmonary support (PCPS) in a patient with pheochromocytoma.
2000 Oct
Antenatal dexamethasone enhances surfactant protein synthesis in the hypoplastic lung of nitrofen-induced diaphragmatic hernia in rats.
2000 Oct
Role of caspases in dexamethasone-induced apoptosis and activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase in human eosinophils.
2000 Oct
Endotoxin augments cerebral hyperemic response to halothane by inducing nitric oxide synthase and cyclooxygenase.
2000 Oct
Endocrinologic and psychological effects of short-term dexamethasone in anorexia nervosa.
2000 Sep
ECT administration in a patient after craniotomy and gamma knife surgery: a case report and review.
2000 Sep
Modification of biophysical properties of lung epithelial Na(+) channels by dexamethasone.
2000 Sep
Involvement of tyrosine hydroxylase up regulation in dexamethasone-induced hypertension of rats.
2000 Sep 8
Intractable nausea attributable to isolated deficiency of adrenocorticotropic hormone: prompt resolution after administration of glucocorticoid.
2000 Sep-Oct
A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide.
2001 Feb
Molecular and pharmacological evidence for modulation of kinin B(1) receptor expression by endogenous glucocorticoids hormones in rats.
2001 Jan
Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension.
2001 Jan
The clinical impact of metabolic bone disease in coeliac disease.
2001 Jan
Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis.
2001 Jan
Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen.
2001 Jan
Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.
2001 Jan 11
Topical 0.1% indomethacin solution versus topical 0.1% dexamethasone solution in the prevention of inflammation after cataract surgery. The Study Group.
2001 Jan-Feb
Patents

Sample Use Guides

One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly. In
Route of Administration: Other
Caco-2 cells were treated with 1 μM dexamethasone and SGK1 mRNA levels were determined by Northern blot analysis. Figure 1A shows that dexamethasone rapidly induced SGK1 mRNA expression as early as 30 min and maintained the elevated expression for at least 24 h.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:46:36 UTC 2021
Edited
by admin
on Fri Jun 25 20:46:36 UTC 2021
Record UNII
7S5I7G3JQL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXAMETHASONE
EMA EPAR   EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
ISV-305
Code English
DEXASONE
Brand Name English
DEXAMETHASONE [MART.]
Common Name English
DEXAMETHASONE [EP MONOGRAPH]
Common Name English
DEXAMETHASONE COMPONENT OF TOBRADEX ST
Brand Name English
DEXAMETHASONE [WHO-DD]
Common Name English
DEXAMETHASONE [ORANGE BOOK]
Common Name English
DEXAMETHASONE COMPONENT OF CIPRODEX
Brand Name English
DEXAMETHASONE [USP-RS]
Common Name English
LOVERINE
Brand Name English
GAMMACORTEN
Common Name English
DEXAMETASONE
Common Name English
MAXIDEX
Brand Name English
SUPERPREDNOL
Common Name English
FORTECORTIN
Brand Name English
DEXAMETHASONE ACETATE IMPURITY A [EP]
Common Name English
DEXASPORIN COMPONENT DEXAMETHASONE
Brand Name English
IMPURITY A [WHO-IP]
Common Name English
DEXAMETHASONE [JAN]
Common Name English
(11.BETA.,16.ALPHA.)-9-FLUORO-11,17,21-TRIHYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Systematic Name English
DEXA-SINE
Brand Name English
DEXONE
Brand Name English
MAXITROL COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONUM [WHO-IP LATIN]
Common Name English
DEXAMETHASONE COMPONENT OF DEXASPORIN
Brand Name English
NSC-34521
Code English
DEXAMETHASONE [EMA EPAR]
Common Name English
FLUORMETHYLPREDNISOLONE
Common Name English
AEROSEB-DEX
Brand Name English
DEXAMETHASONE [INN]
Common Name English
DEXAMETHASONE COMPONENT OF DEXACIDIN
Brand Name English
BETAMETHASONE IMPURITY A [EP]
Common Name English
DEXASITE
Brand Name English
DEXAMONOZON
Brand Name English
DEXAMETHASONE COMPONENT OF TOBRADEX
Brand Name English
DEXAMETHASONE [VANDF]
Common Name English
DEXAPOS
Brand Name English
LUXAZONE
Brand Name English
DECADRON
Brand Name English
DEXYCU
Brand Name English
TOBRADEX ST COMPONENT DEXAMETHASONE
Brand Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17,21-TRIHYDROXY-16-METHYL-,(11.BETA.,16.ALPHA.)-9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Common Name English
DEXACIDIN COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONE [WHO-IP]
Common Name English
TOBRADEX COMPONENT DEXAMETHASONE
Brand Name English
HEMADY
Brand Name English
HEXADROL
Brand Name English
DECADERM
Brand Name English
DEXAMETHASONE [USP MONOGRAPH]
Common Name English
OZURDEX
Brand Name English
ISOPTO-DEX
Brand Name English
CIPRODEX COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONE [HSDB]
Common Name English
DEXAMETHASONE [MI]
Common Name English
VISUMETAZONE
Common Name English
HEXADECADROL
Common Name English
DEXACORTAL
Brand Name English
9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Systematic Name English
DECASPRAY
Brand Name English
MILLICORTEN
Common Name English
DEXACORTIN
Brand Name English
DEXAMETHASONE COMPONENT OF MAXITROL
Brand Name English
DEXTENZA
Brand Name English
16.ALPHA.-METHYL-9.ALPHA.-FLUOROPREDNISOLONE
Common Name English
APHTHASOLONE
Common Name English
OTO-104
Code English
DEXAMETHASONE [GREEN BOOK]
Common Name English
Classification Tree Code System Code
WHO-ATC R01AD03
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 522.540
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 520.540
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 520.540A
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QD10AA03
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
FDA ORPHAN DRUG 674718
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S01BA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S03BA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC D07XB05
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QR01AD03
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QD07AB19
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QH02AB02
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 17.2
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
FDA ORPHAN DRUG 795620
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS01CB01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QD07XB05
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC C05AA09
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 520.540C
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC R01AD53
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
EMA ASSESSMENT REPORTS OZURDEX (AUTHORIZED: MACULAR EDEMA)
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS02BA06
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
EMA ASSESSMENT REPORTS ORZUDEX (AUTHORIZED: UVEITIS)
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QD07CB04
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S03CA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S02BA06
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS03CA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S01CA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS01BA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
FDA ORPHAN DRUG 115298
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S02CA06
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QR01AD53
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.3
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
LIVERTOX 288
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 522.542
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
NCI_THESAURUS C267
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS03BA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC D07AB19
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS01CA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QC05AA09
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
NDF-RT N0000175450
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S01CB01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
EMA ASSESSMENT REPORTS NEOFORDEX (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC H02AB02
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QA01AC02
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 520.540B
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC A01AC02
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC D10AA03
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 03
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
EU-Orphan Drug EU/3/10/763
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 524.1484G
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QH02BX90
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 520.563
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
FDA ORPHAN DRUG 626318
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC D07CB04
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS02CA06
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
Code System Code Type Description
WIKIPEDIA
DEXAMETHASONE
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
PUBCHEM
5743
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
NCI_THESAURUS
C422
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
USP_CATALOG
1176007
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY USP-RS
LACTMED
Dexamethasone, Topical
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
HSDB
3053
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
MERCK INDEX
M4215
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY Merck Index
RXCUI
3264
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB01234
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DEXAMETHASONE
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY Description: Colourless crystals or a white or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS.Category: Adrenoglucocorticoid. Storage: Dexamethasone should be kept in a tightly closed container, protected from light.
LACTMED
Dexamethasone
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
DRUG CENTRAL
824
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
FDA UNII
7S5I7G3JQL
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
MESH
D003907
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
IUPHAR
2768
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
EPA CompTox
50-02-2
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-003-9
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
EVMPD
SUB07017MIG
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
CAS
50-02-2
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
ChEMBL
CHEMBL384467
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
INN
816
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> INDUCER
TARGET -> AGONIST
BINDING
METABOLIC ENZYME -> INDUCER
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
correction factor: for the calculation of content, multiply the peak area of impurity A by 0.75
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC